Literature DB >> 14991902

Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.

Hetty M van Beerendonk1, Leida B Rozeman, Antonie H M Taminiau, Raf Sciot, Judith V M G Bovée, Anne-Marie Cleton-Jansen, Pancras C W Hogendoorn.   

Abstract

Loss of heterozygosity (LOH) at chromosomal band 9p21 is one of the few consistent genetic aberrations found in conventional chondrosarcoma. This locus harbours two cell-cycle regulators, CDKN2A/p16/INK4A and INK4A-p14ARF, which are inactivated in various human malignancies. It was therefore hypothesized that this locus also plays a role in the development of chondrosarcoma and this locus was investigated at protein, genetic, and epigenetic levels. Loss of p16 protein expression was detected by immunohistochemistry in 12 of 73 central chondrosarcomas and it correlated with increasing histological grade (p = 0.001). Loss of p16 protein expression was not found in 51 enchondromas, which are presumed to be potential precursors of conventional central chondrosarcoma. LOH at 9p21 was found in 15 of 39 chondrosarcomas (38%) but it did not correlate with loss of p16 protein expression. SSCP analysis of p16 did not reveal any mutations in 47 cases. Also, p14 was not the target of LOH, since it gave no aberrant bands on SSCP. To investigate whether an epigenetic mechanism was operating, methylation-specific PCR was used to look at p16 promotor methylation, which was identified in 5 of 30 tumours. However, this did not correlate with protein expression, or with LOH at 9p21. Cytogenetic data were available in a subset of cases. All tumours that showed chromosome 9 alterations also showed LOH and loss of INK4A/p16 protein expression. It is concluded that although some alterations were found at the DNA level and at the promoter expression level, the lack of correlation between LOH, promotor methylation, and protein expression indicates that a locus other than CDKN2A/p16 must be the target of LOH at 9p21. The correlation between INK4A/p16 protein expression and tumour grade, and the retention of expression in enchondromas, indicates that loss of INK4A/p16 protein expression may be an important event during tumour progression from enchondroma to conventional central chondrosarcoma, and in the progression in grade after recurrence of chondrosarcoma. Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991902     DOI: 10.1002/path.1517

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  23 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 2.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

Review 3.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

Review 4.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

5.  Treatment of Bone Tumors.

Authors:  Rajiv Rajani; C Parker Gibbs
Journal:  Surg Pathol Clin       Date:  2012-03

6.  PTHR1 mutations associated with Ollier disease result in receptor loss of function.

Authors:  Alain Couvineau; Vinciane Wouters; Guylène Bertrand; Christiane Rouyer; Bénédicte Gérard; Laurence M Boon; Bernard Grandchamp; Miikka Vikkula; Caroline Silve
Journal:  Hum Mol Genet       Date:  2008-06-17       Impact factor: 6.150

Review 7.  Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Authors:  Xing Dai; Wei Ma; Xijing He; Rajiv Kumar Jha
Journal:  Med Sci Monit       Date:  2011-08

8.  Human Chondrosarcoma Cells Acquire an Epithelial-Like Gene Expression Pattern via an Epigenetic Switch: Evidence for Mesenchymal-Epithelial Transition during Sarcomagenesis.

Authors:  Matthew P Fitzgerald; Francoise Gourronc; Melissa L T Teoh; Matthew J Provenzano; Adam J Case; James A Martin; Frederick E Domann
Journal:  Sarcoma       Date:  2011-03-17

9.  Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets.

Authors:  Anne C Onishi; Alexander M Hincker; Francis Y Lee
Journal:  Sarcoma       Date:  2010-12-30

10.  Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.

Authors:  Jolieke G van Oosterwijk; Danielle de Jong; Maayke A J H van Ruler; Pancras C W Hogendoorn; P D Sander Dijkstra; Carla S P van Rijswijk; Isidro Machado; Antonio Llombart-Bosch; Karoly Szuhai; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.